Supplementary table 1. Overview of clinical samples and patient characteristics

CRC patient	Tumour	Normal	Lymph node	PBMC	MMR status	HLA class I status	Tumour location	Clinical stage	Neo-adjuvant therapy	Tumour mutational burden*
S00016	Tumour	х	х	PBMC	MMR-p	Positive	Rectum	$I(T_2N_0M_0)$	Yes	Low
S00030	Tumour	х	LN	PBMC	MMR-p	Positive	Ascendens	II $(T_3N_0M_0)$	No	Low
S00044	Tumour	х	LN	PBMC	MMR-p	Positive	Sigmoid	III $(T_3N_2M_0)$	No	Low
S00045	Tumour	х	х	PBMC	MMR-p	Positive	Rectum	III $(T_3N_1M_0)$	Yes	Low
S00046	Tumour	х	LN	x	MMR-d	Loss	Ascendens	$I(T_2N_0M_0)$	No	
S00049	Tumour	х	LN	x	MMR-p	Weak	Ascendens	II $(T_3N_0M_0)$	No	
S00050	Tumour	х	LN	PBMC	MMR-p	Weak	Sigmoid	III $(T_2N_1M_0)$	No	Low
S00052	Tumour	х	LN	x	MMR-d	Loss	Ascendens	III $(T_3N_2M_0)$	No	High
S00056	Tumour	х	LN	PBMC	MMR-p	Positive	Sigmoid	IV $(T_1N_0M_1)$	No	Low
S00084	Tumour	х	LN	PBMC	MMR-d	Loss	Sigmoid	II $(T_3N_0M_0)$	No	High
S00096_1	Tumour	х	LN	x	MMR-d	Loss	Sigmoid	$I(T_2N_0M_0)$	No	
S00096_2	Tumour	х	LN	x	MMR-d	Loss	Transversum	$I(T_2N_0M_0)$	No	
S00096_3	Tumour	x	LN	x	MMR-d	Loss	Transversum	$I(T_2N_0M_0)$	No	
S00096_4	Tumour	х	LN	x	MMR-d	Loss	Ascendens	$I(T_2N_0M_0)$	No	
S00096_5	Tumour	х	LN	x	MMR-d	Loss	Ascendens	$I(T_2N_0M_0)$	No	
S00102	Tumour	x	LN	РВМС	MMR-d	Loss	Ascendens	III $(T_4N_1M_0)$	No	High
S00104	Tumour	х	LN	x	MMR-p	Positive	Ascendens	II $(T_3N_0M_0)$	No	
S00105	Tumour	х	LN	x	MMR-p	Positive	Sigmoid	$I(T_2N_0M_0)$	No	
S00117	Tumour	Normal	LN	PBMC	MMR-p	Loss	Rectum	$I(T_2N_0M_0)$	No	Low
S00120	Tumour	Normal	х	РВМС	MMR-p	Positive	Rectum	III $(T_3N_1M_0)$	Yes	Low
S00133	Tumour	Normal	х	x	MMR-p	Positive	Sigmoid	III $(T_3N_1M_0)$	No	
S00138	Tumour	Normal	LN	PBMC	MMR-p	Positive	Sigmoid	III $(T_1N_1M_0)$	No	Low
S00140	Tumour	Normal	х	РВМС	MMR-p	Positive	Rectum	$I(T_2N_0M_0)$	Yes	Low
S00141	Tumour	Normal	x	x	MMR-p	Positive	Sigmoid	IV $(T_3N_1M_1)$	No	
S00143	Tumour	Normal	LN	х	MMR-p	Positive	Coecum	II $(T_4N_0M_0)$	No	
S00146	Tumour	Normal	LN	PBMC	MMR-p	Positive	Rectum	$I(T_2N_0M_0)$	Yes	
S00150	Tumour	Normal	LN	x	MMR-d	Loss	Ascendens	II $(T_4N_0M_0)$	No	
S00151	Tumour	Normal	LN	PBMC	MMR-p	Positive	Coecum	$I(T_2N_0M_0)$	No	Low
S00155	Tumour	Normal	х	PBMC	MMR-p	Positive	Rectum	$I(T_1N_0M_0)$	No	
S00159	Tumour	Normal	LN	x	MMR-d	Loss	Coecum	III $(T_3N_1M_0)$	No	
S00164	Tumour	Normal	LN	РВМС	MMR-p	Loss	Descendens	II $(T_3N_0M_0)$	No	
S00167	Tumour	Normal	LN	x	MMR-d	Loss	Ascendens	$I(T_2N_0M_0)$	No	
S00172	Tumour	Normal	х	РВМС	MMR-p	Positive	Rectum	$I(T_2N_0M_0)$	No	
S00184	Tumour	Normal	LN	РВМС	MMR-p	Positive	Sigmoid	III $(T_1N_1M_0)$	No	
S00202	Tumour	Normal	х	РВМС	MMR-d	Loss	Transversum	II $(T_3N_0M_0)$	No	

^{*}Tumour mutational burden data was available for selected samples that had been characterized by whole exome sequencing and was defined as low or high based on a 10 mutations per megabase threshold.